Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 July 2021Next earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:37:18 GMTDividend
Analysts recommendations
Institutional Ownership
RNAZ Latest News
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data from its Phase 0 clinical trial with radiolabeled TTX-MC138 suggesting anti-tumor activity. New results from the patient dosed in this trial indicate that a microdose of radiolabeled TTX-MC138 resulted in significant inhibition of the drug candidate's molecular target, miRNA-10b, in the patient's blood.
TransCode Therapeutics (NASDAQ: RNAZ) shares are declining after the company announced its upcoming annual shareholder meeting on June 13, 2024 at 9:30 a.m Eastern Time.
TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Friday after the oncology company announced plans for a public share offering. TransCode Therapeutics hasn't yet revealed details of the proposed public stock offering.
TransCode Therapeutics (NASDAQ: RNAZ ) stock is falling hard on Tuesday after the medical company announced a public share offering. According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each.
TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monday, before coming back down to earth with an after-hours equity raise. On the back of preclinical results the RNA oncology stock traded as high as $3.20 and closed at $2.55, from a starting price of 66 cents.
Enlivening a soft Monday session on Wall Street, TransCode Therapeutics (NASDAQ: RNAZ ) saw its shares drive up 300% earlier this morning before settling around 240% up in the early afternoon session. Catapulting sentiment was news that TransCode's lead therapeutic candidate, TTX-MC138, demonstrated encouraging pre-clinical results.
TransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice models bearing human glioblastoma multiforme (GBM) tumors. Shares of the Boston-based RNA oncology company added 30.8.1% to US$2.71 in early trade on Monday.
TransCode Therapeutics Inc. (RNAZ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
What type of business is TransCode Therapeutics?
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
What sector is TransCode Therapeutics in?
TransCode Therapeutics is in the Healthcare sector
What industry is TransCode Therapeutics in?
TransCode Therapeutics is in the Biotechnology industry
What country is TransCode Therapeutics from?
TransCode Therapeutics is headquartered in United States
When did TransCode Therapeutics go public?
TransCode Therapeutics initial public offering (IPO) was on 08 July 2021
What is TransCode Therapeutics website?
https://www.transcodetherapeutics.com
Is TransCode Therapeutics in the S&P 500?
No, TransCode Therapeutics is not included in the S&P 500 index
Is TransCode Therapeutics in the NASDAQ 100?
No, TransCode Therapeutics is not included in the NASDAQ 100 index
Is TransCode Therapeutics in the Dow Jones?
No, TransCode Therapeutics is not included in the Dow Jones index
When does TransCode Therapeutics report earnings?
Next earnings report date is not announced yet